Abstract
Multiple sclerosis is the most frequent immunopathological disease of the central nervous system and also the most frequent neurological condition leading to the disability of young people in our region. First disease modifying drug treating relapsing-remitting form of the disease - interferon beta - was introduced in 1993.
Currently, group of these drugs comprises more than ten medications and is still growing. Last registered drug is monoclonal antibody ocrelizumab (Ocrevus), that as the first one proved efficacy also in primary-progressive form of multiple sclerosis.
The article provides fundamental information about efficacy, safety and indications to ocrelizumab treatment in multiple sclerosis including initial experiences and important questions from the clinical practice.